Basket
Total :-
×
Order now
International
English
Login

Early detection of BRCA1 and BRCA2 variants predisposing breast and ovarian cancer saves lives.

Easy: A risk-free buccal swab for DNA collection that can be self-performed at home, non-invasive and painless

Comprehensive: Entire BRCA1 and BRCA2 genes screening · All pathogenic variants detected

Accurate: Highest sensitivity and specificity · CE-IVD and ISO13485 certified key processes · Swiss quality

Early: Every woman at any age is eligible to be screened · Earlier detection allows most effective preventive action for the whole family

Fast: Results issued within 2 weeks, avoid stressful waiting

The leading scientists advocate for BRCA1 and BRCA2 genetic screening for every woman at about age 30 as a part of routine medical care. Early detection of actionable mutations is vital for cancer prevention.

All cancer is genetic - Early detection = effective prevention

Cancer is a serious disease due to deleterious mutation in specific genes that induces the cells to grow in a non controlled and abnormal manner, killing normal cells and with the potential to spread to other parts of the body.

Breast cancer is the most lethal malignancy in women across the world with over 1.676.000 new cases diagnosed every year, and the most common cancer in Europe (500.000 new cases every year), with growing incidence rates. It affects 1 in 8 women (~12%) and is strongly related to age. Between 5-10% of breast cancers are hereditary.

Ovarian cancer is the fifth most common malignancy in women across Europe with over 65.000 new cases diagnosed every year. It affects 14 in 1000 women (~1,4%) and is strongly related to age. About 15% of ovarian cancers are hereditary.


Lifetime risk of developing cancer

Male Male (Projection) Female Female (Projection) Persons Persons (Projection)

BRCA1 and BRCA2 mutations are the most significant risk factors for breast and ovarian cancer

The Breast Cancer (BRCA) 1 and 2 genes were first identified in the early 1990s and represent the most significant and well characterized genetic risk factors identified for breast and ovarian cancers.

This discovery has foundamentally changed the management of hereditary breast and ovarian cancer.

Germline mutations in BRCA1 and BRCA2 are the most common cause of hereditary breast cancer, and also increase the risk of other cancers for both men and women.

This discovery has foundamentally changed the management of hereditary breast and ovarian cancer.




Increased risk of breast and ovarian cancer due to BRCA mutations

Ovarian Cancer Breast Cancer Risk of Cancer By Age 70 (%) BRCA1 Carrier BRCA2 Carrier

Safe and early prevention for the whole family

The implications of identifying a gene mutation are far-reaching and include not only the physical risk of cancer for you and your family, but also the psychological and financial impact that the knowledge can have on the whole family.

First-degree relatives of a BRCA carrier have a much higher risk of developing the disease. Each child of a BRCA mutation-carrier parent has a 50% chance of inheriting the mutation. A family member affected with breast cancer by age 40 further increases the risk for the rest of the family.

About 50% of women with mutations in BRCA1 or BRCA2 genes have no family history of breast or ovarian cancer and ignore they carry cancer-causing mutations. A survey revealed that only 19% of US primary care physicians accurately assessed family history for BRCA1 and BRCA2 testing.

Serenity detects hereditary and non-hereditary (“de novo”) mutations, allowing tailored treatment strategies and personalized therapies.

Women with inherited BRCA mutations

About
50%
Have
no family
history of
cancer
About
50%
Have
family
history of
cancer

Serenity, a Genoma product highly efficient next generation sequencing

A. DNA extraction from buccal swabs.
B. Sequencing of DNA fragments coding for BRCA1 and BRCA2 genes.
C. Library is sequenced by Next Generation Sequencing.
D. Sequencing information is analised through bioinformatics.
E. Analysis of the founded variant(s) to determine their pathogenicity.

Clear report, accurate results help you to protect your health

Within 2 weeks Genoma delivers the most accurate and comprehensive lecture of your BRCA1 and BRCA2 genes.

Our onco-geneticists will report the relevant variant(s) detected in your BRCA1 and BRCA2 genes and their pathogenicity. Based on the recorded clinical cases from the European leader in Data Driven Medicine, our experts classify the variants from benign to highly pathogenic. Relevant variants increase or are likely to increase the risk of developing cancer.

  • A pathogenic variant or deleterious mutation has a serious negative impact on the function of the gene. The risk of developing cancer is significantly higher.
  • A begin variant has no impact on the function of the gene: even with this difference in its code, there is no deleterious impact. A large amount of the population carries this variant with no development of cancer. As a consequence, “benign variant” will not be reported.
  • A variant of unknown significance may have an impact on the function of the gene but the cancer risk has not yet been determined with certainty.

References:

  • Miki et al., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, 1994
  • Wooster et al., Identification of the breast cancer susceptibility gene BRCA2, Nature, 1996
  • King et al., Population based screening for BRCA-1 and BRCA-2, 2014 Lasker Award, JAMA, 2014
  • Lifetime risk projections calculated by the Statistical Information Team at Cancer Research UK. Based on using data provided by Wolfson Institute of Preventive Medicine, Queen Mary University of Londonon request September 2012
  • National Cancer Institute, Genetics of Breast and Ovarian Cancer, http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/ HealthProfessional/page2#Section_113, 2013
  • Petrucelli N, et al. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. Gene Reviews, http://www.ncbi.nlm.nih.gov/books/NBK1247, 2013
  • Royal College of Obstetricians & Gynaecologists, Management of Women with a Genetic Predisposition to Gynaecological Cancers, Scientific Impact Paper No.48, 2015
  • Susan J Ramus and Simon A. Gayther, The Contribution of BRCA1 and BRCA2 to Ovarian Cancer, 2009
  • Yang X, Wu J, Lu J, Liu G, Di G, Chen C, et al. Identification of a Comprehensive Spectrum of Genetic Factors for Hereditary Breast Cancer in a Chinese Population by Next-Generation Sequencing. PLoS ONE 10(4): e0125571. doi:10.1371/journal.pone.0125571, 2015
  • U.S. National Library of Medicine, PubMed Health, Breast Cancer, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001911, 2014
  • U.S. National Library of Medicine, PubMed Health, Ovarian Cancer, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH000189, 2014
  • Balmana et al., BRCA in breast cancer: ESMO Clinical Recommendations, Annals of Oncology, 2009
  • Ferlay et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, Lyon, France, 2013
  • Heanue et al., Cancer Incidence in Five Continents, Vol. IX IARC Scientific Publications No. 160. IARCPress, 2007
  • Howlader et al., SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute, 2013
  • Narod et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. American Journal of Human Genetics, 2003
  • American Journal of Preventive Medicine 40 (1):61-66, 2011
  • Chen S, Parmigiani G, Meta-analysis of BRCA1 and BRCA2 penetrance, Journal of Clinical Oncology, 2007
  • Ferlay et al., Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer, 2013
  • Hughes-Davies et al., EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer, Cell, 2003
  • Offit et al., Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers. Journal of Clinical Oncology, 2002

How Serenity works

Purchase your Serenity kit - Receive your kit shortly at home - Perform the collection - Return the sample free of charge - Receive your results!

Purchase online

Add Serenity kit to your basket, Click on the order button and follow the simple instructions.

Sampling

You will find in your kit everything you need to perform the sample collection. Simply follow the detailed Instructions For Use that you will find inside your kit.

Free shipping

The shipping is entirely covered by Genoma. Simply follow the instructions inside your kit to return your sample for analysis.

Analysis

Your sample will be analysed in the most advanced laboratories. They use cutting edge technology to offer you the most accurate results in the shortest possible time.

Demo version